
Colorado agrees to 2 wolf compensation claims that will nearly bust its budget
The 11-member commission approved more than $340,000 in compensation claims at its meeting Wednesday in Denver: $287,407 to Farrell Livestock and $56,008 to Bruchez and Sons. Both ranch in Grand County.
Colorado Parks and Wildlife, which conducted the compensation claim process with the ranchers, recommended the commission approve the claims.
Conway Farrell told the Coloradoan after the claim was approved that he was relieved but said the compensation doesn't make it whole.
"We could get a half million dollars out of this deal and it wouldn't touch the losses we actually had to sustain our operation," said Farrell, who attended the meeting. "We need the money to stay in business. This is money we usually would have had last fall to go through another year of ranching."
Farrell said ranchers are working with the state wildlife agency to refine the compensation process. Last year was the first year the state's current wolf recovery compensation program was in place.
Colorado Parks and Wildlife Director Jeff Davis said the agency is working with Colorado State University to standardize livestock data that it will share with ranchers to "work out the bugs" from the first phase of the claims process.
"This (wolf restoration) is new," Davis told commissioners. "Everyone feels a lot of anxiety, fear, anger around the wolf restoration effort. We feel that, too, internally. We are working through it together."
Commissioners said they heard from the public a request for a transparency regarding wolf compensation, especially regarding the Farrell claim.
Travis Black, Colorado Parks and Wildlife's Northwest Regional manager, worked with Grand County ranchers to rectify their claims.
Black broke down Farrell's approximate compensation approved at Wednesday's meeting this way:
$178,000 for reduced weight on 1,470 head of calves compared to three years previous to 2024
$90,000 for a nearly 3% conception rate reduction compared to three years previous to 2024
$15,000 for confirmed wolf depredations of 15 livestock
$3,500 for missing sheep
Wednesday's vote to approve the more than $340,000 in wolf compensation claims will nearly consume the state's $350,000 budget for wolf compensation to ranchers in 2024.
And there remain other outstanding compensation claims. It was noted at Wednesday's meeting there is another claim of approximately $112,000 for missing cattle from the Farrell Ranch. Another Grand County rancher has a $100,000 claim, as previously reported by the Coloradoan.
Those claims are expected to be heard by the commission at meetings this summer.
A bill created a wolf compensation fund using the state's general fund, species conservation trust fund, Colorado nongame conservation and wildlife restoration cash funds and wildlife cash fund, excluding money egnerated from the sale of hunting and fishing licenses.
The Coloradoan sought to ask Davis during a break in Wednesday's meeting if the current wolf compensation program was sustainable. Colorado Parks and Wildlife spokesperson Travis Duncan said any questions would need to be emailed to him and that he would address them with Davis.
Duncan said in an emailed response, which he attributed to himself and not the director, that a number of unique factors contributed to the larger claim approved Wednesday that were not predicted at the time of fiscal estimates, which were based prior to the release of wolves in Colorado and extrapolated from other states.
Duncan added the agency this year expanded and improved its conflict minimization program for Colorado livestock producers, which could impact the number and amount of claims submitted in the future.
The narrow voter passage of Proposition 114 in 2020 required the reintroduction of wolves and that livestock producers be compensated for their losses due to the predator.
The state wolf recovery plan established the process for how ranchers would be compensated. That included 'fair market value' for livestock injured and killed by wolves up to $15,000 per animal.
It also included ranchers experiencing a confirmed wolf depredation the option of recouping losses, including missing livestock and reduced weight loss and conception rates due to the stress wolves place on livestock.
Davis told commissioners Colorado is to his knowledge the only western state that pays for weight loss and conception rates reductions due to the presence of wolves.
Colorado Parks and Wildlife staff and commissioners noted they had received many public comments questioning the legitimacy of the state's wolf compensation program, some believing compensation to be too favorable to ranchers.
Dallas May, commission chair who ranches in southeast Colorado, said despite the criticism of the compensation plan that he believed Farrell's claim could have been higher. He said that is due to Farrell's cattle being specially bred for high altitude. He added there is a likelihood of a cow not bearing a calf failing in future years to calf again.
"I know there's been a lot of criticism, but I think people have to understand what this does to an operation," he said at the meeting. "I can tell you that one event upon a ranch affects the entire ranch. It has a huge impact on those people affected."
This article originally appeared on Fort Collins Coloradoan: Colorado pays rancher record wolf compensation claim amount
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26-06-2025
- Yahoo
Circle's stock plummets 25% over two days as investors flock to this other stablecoin play
Circle Internet Group Inc. shares lost more steam on Wednesday, three weeks after the company's splashy initial public offering, with focus now shifting to other stablecoin plays. Circle's stock CRCL has tumbled 24.6% over the past two trading days, while Coinbase Global Inc. shares COIN have run up 15.5% over the same stretch to close Wednesday just 0.6% away from a record high. My job is offering me a payout. Should I take a $61,000 lump sum or $355 a month for life? 'He doesn't seem to care': My secretive father, 81, added my name to a bank account. What about my mom? JPMorgan has a new way of forecasting the stock market — and there's a surprising finding Israel-Iran clash delivers a fresh shock to investors. History suggests this is the move to make. I'm 75 and have a reverse mortgage. Should I pay it off with my $200K savings — and live off Social Security instead? The past two days mark a departure from Circle's stunning performance since its June 5 debut. Yet the pullback of Circle's stock was 'not surprising,' as its earlier rise was likely overdone, Peter Eberle, chief investment officer at crypto investment firm Castle Funds, said in an interview. The company's shares hit an intraday peak of $298.99 on Monday, or roughly 10 times its IPO price, according to FactSet. They closed Wednesday down 10.8% at $198.62. A boost for Circle on Monday was attributed in part to the announcement by fintech company Fiserv Inc. FI that it would join with Circle to develop its own stablecoin. Enthusiasm on the regulatory front has been another factor in pushing Circle's stock higher. The Senate last week passed a new bill that aims to regulate stablecoins, a type of crypto whose value is pegged to another asset, often the U.S. dollar. Should the bill — which now heads to the House for a vote — become law, crypto bulls see potential for it to drive wider adoption of dollar-linked stablecoins. But for now, investors may be taking profits in Circle, as its rapid rise was 'beyond fundamental sense,' according to Alexander Blume, chief executive at crypto hedge fund Two Prime. Blume said Circle's retreat and the relative strength of Coinbase may also suggest shares of the newly public company became overvalued. Sean Farrell, head of digital-asset strategy at Fundstrat, echoed the point last week. 'I do think at some point either Circle would come down to a more realistic valuation or Coinbase would come up to meet it,' Farrell said in a recent video for Fundstrat's clients. 'The most likely scenario is that we probably see some substantial drawdown in Circle and a rerating higher in Coinbase.' Coinbase shares some profits with Circle generated from its flagship USDC USDCUSD stablecoin. To break down Farrell's thesis, Circle has been paying Coinbase handsomely for its role in distributing and promoting USDC. In 2024, Circle paid $907.9 million to Coinbase, over half of Circle's total revenue at $1.7 billion, according to public filings. For the three months that ended March 31, 2025, Circle paid Coinbase $298.8 million, over half of Circle's total revenue of about $578.6 million for the same period. While both Coinbase and Circle could benefit from passage of the stablecoin bill, Coinbase could face more upside if other crypto-friendly regulations were passed under the Trump administration, according to Mark Palmer, equity research analyst at the Benchmark company. In particular, Coinbase could get a lift should the Digital Asset Market Clarity Act become law. The legislation aims to divide oversight between the U.S. Securities and Exchange Commission and the Commodity Futures Trading Commission and to create a regulatory framework for crypto market structure, Palmer said. Earlier this month, the House Committee on Financial Services and Agriculture advanced the bill to the full House of Representatives. Coinbase's stock rallied as much as 7.1% to an intraday high of $369.28 early in Wednesday's session, to top the Nov. 9, 2021 record close of $357.39, before pulling back to close at $355.37. Citizens analyst Devin Ryan believes there's still plenty of upside for Coinbase's stock, as his $400 price target is 12.6% above current levels. 'We see a multitude of other potential multi-billion dollar revenue streams forming at Coinbase, which we anticipate can support a higher valuation from here, even after the strong move in June,' Ryan said. Steve Gelsi contributed. Why this banking proposal may mean good news for the bond market and investors We're living in 'end times' when you can't retire on $1 million My cousin died before claiming his late father's $2 million estate. Will I be next in line for this inheritance? Israel-Iran conflict poses three challenges for stocks that could slam market by up to 20%, warns RBC Coinbase's stock sees a 'golden cross.' Why it may not be a bullish signal to buy. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
25-06-2025
- Business Insider
Jefferies Remains a Hold on Metso Outotec (0MGI)
Jefferies analyst David Farrell maintained a Hold rating on Metso Outotec (0MGI – Research Report) today and set a price target of €11.00. The company's shares closed yesterday at €10.59. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Farrell is a 4-star analyst with an average return of 9.1% and a 57.86% success rate. Farrell covers the Industrials sector, focusing on stocks such as Chemring, Volution, and FLSmidth & Co. A/S. Metso Outotec has an analyst consensus of Hold, with a price target consensus of €9.98.
Yahoo
18-06-2025
- Yahoo
ResMed's Q1 Earnings Call: Our Top 5 Analyst Questions
ResMed's first quarter results were met with a strong market response, reflecting in-line revenue and profit performance alongside notable margin expansion. Management credited manufacturing and logistics efficiencies, positive product mix shifts, and sustained demand in both devices and masks as primary contributors to improved profitability. CEO Mick Farrell emphasized the benefits of investments in automation and U.S.-based production, stating, 'Our results are a testament to the work that we do to enhance sleep health, breathing health, and health care delivery in the home.' The company also highlighted robust growth across geographies and a disciplined approach to operational spending. Is now the time to buy RMD? Find out in our full research report (it's free). Revenue: $1.29 billion vs analyst estimates of $1.29 billion (7.9% year-on-year growth, in line) Adjusted EPS: $2.37 vs analyst estimates of $2.36 (in line) Operating Margin: 33%, up from 31.3% in the same quarter last year Constant Currency Revenue rose 9% year on year (7% in the same quarter last year) Market Capitalization: $36.6 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Lyanne Harrison (Bank of America) asked for a breakdown of margin expansion factors. CFO Brett Sandercock explained that manufacturing efficiencies, distribution improvements, and favorable product mix all contributed meaningfully. Margaret Kaczor (William Blair) inquired about sleep lab backlogs and the impact of new diagnostic tools. CEO Mick Farrell detailed metrics tracked on patient throughput and outlined how Night Owl aims to shorten diagnosis-to-therapy timelines. Suraj Kalia (Goldman Sachs) questioned the rationale behind increasing share buybacks amid demand and tariff uncertainties. CFO Brett Sandercock cited a strong balance sheet and cash flows, while Farrell emphasized a balanced approach to capital allocation, including tuck-in acquisitions. Anthony Petrone (Mizuho Group) sought clarity on the impact of GLP-1 medications on patient funnel expansion. Farrell noted early signs of increased referrals from primary care physicians and ongoing educational efforts to drive demand. David Bailey (Morgan Stanley) raised concerns about CPAP adherence among patients using GLP-1 drugs. Farrell responded that adherence rates remain strong and that lifestyle changes linked to these medications may even enhance long-term compliance. In the coming quarters, the StockStory team will be monitoring (1) the operational ramp-up and cost benefits from the new California manufacturing facility, (2) adoption rates for the Night Owl diagnostic tool and expanded software platforms, and (3) the effectiveness of adherence and resupply initiatives in boosting recurring revenue. We will also track regulatory developments and their potential impact on ResMed's global supply chain and reimbursement landscape. ResMed currently trades at $250.53, up from $214.36 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio